SOST and osteoporosis: Higher serum levels of sclerostin have been linked to increased risk for fracture in aging individuals (Ardawi et al., 2012), and compounds that decrease SOST expression are targets for treatment of osteoporosis (Delgado‐Calle et al., 2017), so that the unchanged level seen in centenarians may describe a protective mechanism.